Medulloblastoma: signalling a change in treatment - PubMed (original) (raw)
Review
Medulloblastoma: signalling a change in treatment
Richard J Gilbertson. Lancet Oncol. 2004 Apr.
Abstract
Medulloblastoma is the most common malignant brain tumour that occurs during childhood. Multimodality treatment regimens have substantially improved survival in this disease; however, the tumour is incurable in about a third of patients with medulloblastoma, and current treatment has a detrimental effect on long-term survivors. Drugs that target cell-signalling pathways provide an alternative to conventional cytotoxic approaches to treatment of cancer. Several pathways have been implicated in medulloblastoma formation, and knowledge of these is now being used to develop new ways of treating children with medulloblastoma.
Similar articles
- Failure of a medulloblastoma-derived mutant of SUFU to suppress WNT signaling.
Taylor MD, Zhang X, Liu L, Hui CC, Mainprize TG, Scherer SW, Wainwright B, Hogg D, Rutka JT. Taylor MD, et al. Oncogene. 2004 Jun 3;23(26):4577-83. doi: 10.1038/sj.onc.1207605. Oncogene. 2004. PMID: 15077159 - Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice.
Rao G, Pedone CA, Del Valle L, Reiss K, Holland EC, Fults DW. Rao G, et al. Oncogene. 2004 Aug 12;23(36):6156-62. doi: 10.1038/sj.onc.1207818. Oncogene. 2004. PMID: 15195141 - Hitting the target in medulloblastoma therapy.
Bradbury J. Bradbury J. Drug Discov Today. 2004 Dec 1;9(23):994-5. doi: 10.1016/S1359-6446(04)03289-1. Drug Discov Today. 2004. PMID: 15574311 No abstract available. - Medulloblastoma: developmental mechanisms out of control.
Marino S. Marino S. Trends Mol Med. 2005 Jan;11(1):17-22. doi: 10.1016/j.molmed.2004.11.008. Trends Mol Med. 2005. PMID: 15649818 Review. - Clinical management of medulloblastoma in adults.
Eisenstat DD. Eisenstat DD. Expert Rev Anticancer Ther. 2004 Oct;4(5):795-802. doi: 10.1586/14737140.4.5.795. Expert Rev Anticancer Ther. 2004. PMID: 15485314 Review.
Cited by
- Measuring the optical characteristics of medulloblastoma with optical coherence tomography.
Vuong B, Skowron P, Kiehl TR, Kyan M, Garzia L, Sun C, Taylor MD, Yang VX. Vuong B, et al. Biomed Opt Express. 2015 Mar 25;6(4):1487-501. doi: 10.1364/BOE.6.001487. eCollection 2015 Apr 1. Biomed Opt Express. 2015. PMID: 25909030 Free PMC article. - Outcome of children with posterior fossa medulloblastoma: a single institution experience over the decade 1994-2003.
Kombogiorgas D, Sgouros S, Walsh AR, Hockley AD, Stevens M, Grundy R, Peet A, English M, Spooner D. Kombogiorgas D, et al. Childs Nerv Syst. 2007 Apr;23(4):399-405. doi: 10.1007/s00381-006-0258-5. Epub 2006 Nov 22. Childs Nerv Syst. 2007. PMID: 17119978 Clinical Trial. - Embryonic tumours of the central nervous system.
Navajas Gutiérrez A, Fernández-Teijeiro Alvarez A. Navajas Gutiérrez A, et al. Clin Transl Oncol. 2005 Jun;7(5):219-27. doi: 10.1007/BF02712821. Clin Transl Oncol. 2005. PMID: 15960935 Review. No abstract available. - Medulloblastoma-translating discoveries from the bench to the bedside.
Gajjar AJ, Robinson GW. Gajjar AJ, et al. Nat Rev Clin Oncol. 2014 Dec;11(12):714-22. doi: 10.1038/nrclinonc.2014.181. Epub 2014 Oct 28. Nat Rev Clin Oncol. 2014. PMID: 25348790 Review.